Use of interferon beta 1b for multiple sclerosis

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7067.1263 (Published 16 November 1996) Cite this as: BMJ 1996;313:1263

Patients will put up with side effects because of their desire to beat the disease

  1. Miriam Chellingsworth
  1. Retired consultant geriatrician 1 Montville Drive, Stafford ST17 9XJ

    EDITOR,—As a physician who has both multiple sclerosis and a doctorate in clinical pharmacology, I am probably in a unique position to answer Peter Harvey's question of why interferon beta 1b was licensed.1

    Multiple sclerosis, particularly the relapsing-remitting form, is a notoriously difficult illness on which …

    View Full Text

    Sign in

    Log in through your institution